Tag: Alkeus Pharmaceuticals
-
Tarsus Bets Up to $800 Million on a Deuterated Vitamin A Drug
Tarsus is acquiring Alkeus for up to $800 million, gaining gildeuretinol, a Phase 3 deuterated vitamin A therapy for Stargardt disease.
Tarsus is acquiring Alkeus for up to $800 million, gaining gildeuretinol, a Phase 3 deuterated vitamin A therapy for Stargardt disease.